健倍苗苗(02161)发布截至2025年3月31日止年度的年度业绩，该集团取得收益7.82亿港元，同比增加20.65%;公司权益持有人应占溢利1.97亿港元，同比增加51.2%;每股盈利24.08港仙，拟派付末期股息每股 11.5港仙。

健倍苗苗于2025财年录得强劲的财务业绩，反映我们有能力推动对深受信赖的高品质产品的持续需求。我们的品牌医疗保健业务收益增至7.82亿港元，按年增长20.7%。毛利增长22.4%至4.14亿港元，而权益持有人应占综合溢利则飙升51.2%至1.97亿港元。

此业绩表现得益于我们的旗舰品牌何济公、保济丸及飞鹰活络油的卓越增长，以及浓缩中药颗粒业务的稳定贡献。我们的战略重点是整合线上及线下渠道的销售及营销，同时开展高影响力的创意品牌活动，扩大电子商务的覆盖面，并持续优化成本，以缔造佳绩。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.